Revenue - Cartesian Therapeutics Inc (NASDAQ:RNAC) - Alpha Spread

Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 16.54 USD 5.82% Market Closed
Market Cap: 353.6m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Cartesian Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cartesian Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cartesian Therapeutics Inc
NASDAQ:RNAC
Revenue
$54.1m
CAGR 3-Years
5%
CAGR 5-Years
126%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55B
CAGR 3-Years
1%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.8B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Revenue
$30.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.3B
CAGR 3-Years
16%
CAGR 5-Years
25%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.5B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
18%

See Also

What is Cartesian Therapeutics Inc's Revenue?
Revenue
54.1m USD

Based on the financial report for Jun 30, 2024, Cartesian Therapeutics Inc's Revenue amounts to 54.1m USD.

What is Cartesian Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
126%

Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Cartesian Therapeutics Inc have been 5% over the past three years , 126% over the past five years .

Back to Top